EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy

Luis Alfredo Gonzalez Guzman, Jose Carlos García Robaina, Javier Barrios Recio, Elena Escudero Arias, Tania Liñares Mata, Raquel Cervera Aznar, Federico De La Roca Pinzón, Lissette Del Carmen Miguel Polo, Luis Arenas Villarroel, Verónica P López Couso iD, Javier Alcover Diaz, David Rodriguez Gil iD und 2 weitere

Vaccines · 13.05.2023 · 11 (5) · 979

DOI: 10.3390/vaccines11050979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 13.05.2023. Verfasst von Luis Alfredo Gonzalez Guzman und 13 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, Hospital Lucus Augusti, 27003 Lugo, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diater Laboratorios S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to explore the safety and efficacy of bee venom immunotherapy without HSA, in real-life patients.

Methods

This is an observational retrospective study developed in seven hospitals in Spain, where patients treated with this immunotherapy were included. They gathered the protocol used to initiate the immunotherapy, adverse reactions, field re-stings, and the patient clinical data (clinical history, biomarkers, and skin prick test).

Results

A total of 108 patients were included. In total, 4 protocols were used (5 weeks reaching 200 μg, and 4, 3, and 2 weeks reaching 100 μg). An incidence of systemic adverse reactions for each 100 injections of 1.5, 1.7, 0, and 0.58, respectively, was found. The demographic data showed not to directly affect the appearance of adverse reactions, except for those having a grade 2 systemic reaction with immunotherapy previously had a grade 4 systemic reaction; the IgE to Apis mellifera was 3 times higher in patients with systemic reactions of grade 1 than in the general group, and other specific IgEs were lower in those with systemic reactions. Most of the patients recognized Api m 1 followed by Api m 10. In the sample, 32% experienced spontaneous re-stings, without presenting systemic reactions, after a year of treatment.

Schlagwörter

Stichwörter der Autor:innen

Api m 10allergy immunotherapybee venomhuman serum albuminhymenoptera venomvaccines

Autor:innen und Institutionen

  • Allergy Department, Hospital Lucus Augusti, 27003 Lugo, Spain.
  • Allergy Department, Nuestra Señora de la Candelaria University Hospital, 38010 Santa Cruz de Tenerife, Spain.
  • Allergy Department, Hospital Provincial de Pontevedra, 36001 Pontevedra, Spain.
  • Allergy Department, Hospital General Universitari de Castelló, 12004 Castelló de la Plana, Spain.
  • Allergy Department, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
  • Allergy Department, Hospital Virgen De La Luz, 16002 Cuenca, Spain.

ORCID-Profile: Verónica P López Couso, David Rodriguez Gil

Förderung

  • Diater Laboratorios S.A.

Zitieren

APA

Gonzalez Guzman, L. A., García Robaina, J. C., Barrios Recio, J., Escudero Arias, E., Liñares Mata, T., Cervera Aznar, R., De La Roca Pinzón, F., Miguel Polo, L. D. C., Arenas Villarroel, L., López Couso, V. P., Alcover Diaz, J., Rodriguez Gil, D., Pelaez, R. P., & Carballada Gonzalez, F. J. (2023). Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy. Vaccines, 11(5), 979. https://doi.org/10.3390/vaccines11050979

Vancouver

Gonzalez Guzman LA, García Robaina JC, Barrios Recio J, Escudero Arias E, Liñares Mata T, Cervera Aznar R, et al. Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy. Vaccines. 2023;11(5):979. doi:10.3390/vaccines11050979

BibTeX
@article{GonzalezGuzman2023,
  author = {Gonzalez Guzman, Luis Alfredo and García Robaina, Jose Carlos and Barrios Recio, Javier and Escudero Arias, Elena and Liñares Mata, Tania and Cervera Aznar, Raquel and De La Roca Pinzón, Federico and Miguel Polo, Lissette Del Carmen and Arenas Villarroel, Luis and López Couso, Verónica P and Alcover Diaz, Javier and Rodriguez Gil, David and Pelaez, Ricardo Palacios and Carballada Gonzalez, Francisco Javier},
  title = {Real-World Safety and Efficacy Clinical Data of an Improved Allergen-Specific Immunotherapy Product for the Treatment of Bee Venom Allergy},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {5},
  pages = {979},
  doi = {10.3390/vaccines11050979}
}
Kostenlos starten →